Ionis Pharmaceuticals IONS Danvatirsen — Revenue
Discontinued — last reported Q4 '18
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 24, 2021, on SEC EDGAR. View the filing →
Questions, answered.
- What does danvatirsen — revenue mean?
- The total net revenue generated specifically from the Danvatirsen product or its associated contractual agreements.
- How do you interpret danvatirsen — revenue?
- An increase indicates growing commercial success, successful milestone achievement, or increased market demand for the specific therapeutic asset. A decrease may signal declining sales, the completion of milestone payments, or competitive pressure in the relevant disease area.
- How does danvatirsen — revenue compare across companies?
- Comparable to product-specific revenue or asset-based licensing revenue reported by other biotechnology firms, often benchmarked against the lifecycle stage of the clinical or commercial asset.